{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:35:20Z","timestamp":1792157720930,"version":"4.4.0"},"reference-count":230,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.tranon.2026.102719","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:16:30Z","timestamp":1772154990000},"page":"102719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis"],"prefix":"10.1016","volume":"66","author":[{"given":"Nouran Walid","family":"Hamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasnaa Salman","family":"Elbeljihy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifaa Atif","family":"Hussin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana Mohamed","family":"Fouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El-Khawaga","family":"OY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-7474","authenticated-orcid":false,"given":"Raghda","family":"W\u2024Magar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tranon.2026.102719_bib0001","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/bjc.2016.402","article-title":"Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer","volume":"116","author":"Rao","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"15","key":"10.1016\/j.tranon.2026.102719_bib0003","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJMcp2209151","article-title":"Screening for Prostate Cancer","volume":"388","author":"Pinsky","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0004","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3390\/ijms24032185","article-title":"Biomarkers of Aggressive Prostate Cancer at Diagnosis","volume":"24","author":"Boehm","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.tranon.2026.102719_bib0005","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1055-9965.EPI-19-1616","article-title":"Diversity of enrollment in prostate cancer clinical trials: current status and future directions. Cancer Epidemiology","volume":"29","author":"Rencsok","year":"2020","journal-title":"Biomark. Prev."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0006","first-page":"211","article-title":"Cancer statistics for african americans, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA: Cancer J. Clin."},{"issue":"21","key":"10.1016\/j.tranon.2026.102719_bib0007","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.3390\/diagnostics13213350","article-title":"Biomarkers for prostate cancer: from diagnosis to treatment","volume":"13","author":"Chen","year":"2023","journal-title":"Diagnostics"},{"issue":"127","key":"10.1016\/j.tranon.2026.102719_bib0008","doi-asserted-by":"crossref","first-page":"127rv3","DOI":"10.1126\/scitranslmed.3003180","article-title":"Beyond PSA: the next generation of prostate cancer biomarkers","volume":"4","author":"Prensner","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0009","doi-asserted-by":"crossref","first-page":"01","DOI":"10.33545\/26648482.2025.v7.i1a.3","article-title":"Emerging biomarkers in cancer detection and prognosis: A comprehensive review","volume":"7","author":"Hussein","year":"2025","journal-title":"Int. J. Immunol."},{"issue":"11","key":"10.1016\/j.tranon.2026.102719_bib0010","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.21037\/tau-23-371","article-title":"Value of digital rectal examination in patients with suspected prostate cancer: a prospective cohort analysis study","volume":"12","author":"Ying","year":"2023","journal-title":"Transl. Androl. Urol."},{"issue":"11","key":"10.1016\/j.tranon.2026.102719_bib0011","article-title":"Clinical Reliability and Diagnostic Value of Digital Rectal Examination in the Detection of Prostate Cancer and Broader Clinical Practice: A Narrative Review","volume":"17","author":"Elmadani","year":"2025","journal-title":"Cureus."},{"issue":"4","key":"10.1016\/j.tranon.2026.102719_bib0012","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.euo.2023.12.005","article-title":"Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis","volume":"7","author":"Matsukawa","year":"2024","journal-title":"Eur. Urol. Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2026.102719_bib0013","article-title":"The Value of Digital Rectal Examination (DRE) in Prostate Cancer Diagnostics","volume":"16","author":"Debo-Aina","year":"2024","journal-title":"Cureus."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0014","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/00369330241279889","article-title":"Is it time to phase out digital rectal examination (DRE) in prostate cancer screening and diagnosis?","volume":"69","author":"Carbin","year":"2024","journal-title":"Scott. Med. J."},{"issue":"10","key":"10.1016\/j.tranon.2026.102719_bib0015","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.urolonc.2017.06.003","article-title":"Physical after-effects in men undergoing prostate biopsy in routine clinical practice: Results from the PiCTure study","volume":"35","author":"Morgan","year":"2017","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.tranon.2026.102719_bib0016","first-page":"1","article-title":"Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature","author":"Cui","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"issue":"8","key":"10.1016\/j.tranon.2026.102719_bib0017","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3390\/ijms20081813","article-title":"A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges","volume":"20","author":"Kohaar","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0018","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1515\/cclm-2019-0693","article-title":"Biomarkers for prostate cancer: prostate-specific antigen and beyond","volume":"58","author":"Duffy","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"issue":"6","key":"10.1016\/j.tranon.2026.102719_bib0019","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1055-9965.EPI-05-0984","article-title":"Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA","volume":"15","author":"Severi","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"8","key":"10.1016\/j.tranon.2026.102719_bib0020","first-page":"97","article-title":"The role of psa biomarkers in early detection of prostate cancer: clinical significance, limitations, and future directions","volume":"3","author":"Oybek o'g","year":"2025","journal-title":"Am. J. Of Appl. Med. Sci."},{"issue":"2","key":"10.1016\/j.tranon.2026.102719_bib0021","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/JU.0000000000000530","article-title":"The role of prostate specific antigen monitoring after holmium laser enucleation of the prostate","volume":"203","author":"Abedali","year":"2020","journal-title":"J. Urol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102719_bib0022","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CU9.0000000000000145","article-title":"Prostate cancer screening: Continued controversies and novel biomarker advancements","volume":"16","author":"Tidd-Johnson","year":"2022","journal-title":"Curr. Urol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0023","doi-asserted-by":"crossref","first-page":"10438","DOI":"10.3390\/ijms140510438","article-title":"Human prostatic acid phosphatase: structure, function and regulation","volume":"14","author":"Muniyan","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"1-3","key":"10.1016\/j.tranon.2026.102719_bib0024","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0167-4781(00)00037-3","article-title":"Expression of human prostatic acid phosphatase gene is regulated by upstream negative and positive elements","volume":"1491","author":"Zelivianski","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1158\/ajc.1936.485a","article-title":"Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland","volume":"28","author":"Gutman","year":"1936","journal-title":"Am. J. Cancer"},{"issue":"23","key":"10.1016\/j.tranon.2026.102719_bib0026","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1038\/sj.onc.1205471","article-title":"Identification and characterization of regulatory elements of the human prostatic acid phosphatase promoter","volume":"21","author":"Zelivianski","year":"2002","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0027","first-page":"24","article-title":"PSA and acid phosphatase in the diagnosis of prostate cancer","volume":"21","author":"Chu","year":"1998","journal-title":"J. Clin. Ligand Assay"},{"key":"10.1016\/j.tranon.2026.102719_bib0028","doi-asserted-by":"crossref","unstructured":"Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., ... & Schellhammer, P. F. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine, 363(5), 411-422.","DOI":"10.1056\/NEJMoa1001294"},{"issue":"8","key":"10.1016\/j.tranon.2026.102719_bib0029","article-title":"Reviving the Acid Phosphatase Test for Prostate Cancer","volume":"17","author":"Cooper","year":"2007","journal-title":"Cancer Netw."},{"issue":"9","key":"10.1016\/j.tranon.2026.102719_bib0030","first-page":"833","article-title":"Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study","volume":"44","author":"Chopra","year":"1991","journal-title":"Arch. Esp. Urol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0031","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/JU.0000000000001453","article-title":"Performance of Prostate Health Index in Biopsy Na\u00efve Black Men","volume":"205","author":"Babajide","year":"2021","journal-title":"J. Urol."},{"issue":"15","key":"10.1016\/j.tranon.2026.102719_bib0032","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.tranon.2026.102719_bib0033","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.juro.2015.02.015","article-title":"Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer","volume":"194","author":"Dinh","year":"2015","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0034","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.eururo.2005.11.007","article-title":"Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology","volume":"49","author":"Chun","year":"2006","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2026.102719_bib0035","doi-asserted-by":"crossref","unstructured":"Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., ... & Moore, C. M. (2018). MRI-targeted or standard biopsy for prostate-cancer diagnosis. New England Journal of Medicine, 378(19), 1767-1777.","DOI":"10.1056\/NEJMoa1801993"},{"issue":"2","key":"10.1016\/j.tranon.2026.102719_bib0036","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","article-title":"Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis","volume":"70","author":"de Rooij","year":"2016","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102719_bib0037","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2302\/kjm.52.86","article-title":"Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer","volume":"52","author":"Mikolajczyk","year":"2003","journal-title":"Keio J. Med."},{"issue":"6","key":"10.1016\/j.tranon.2026.102719_bib0038","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.eururo.2013.01.011","article-title":"Serum isoform [\u2212 2] proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2\u201310 ng\/ml: a multicentric European study","volume":"63","author":"Lazzeri","year":"2013","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0039","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.eururo.2013.12.005","article-title":"Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy","volume":"66","author":"Lughezzani","year":"2014","journal-title":"Eur. Urol."},{"issue":"1 Pt 2","key":"10.1016\/j.tranon.2026.102719_bib0040","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jfma.2018.05.001","article-title":"The application of p2PSA % and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center","volume":"118","author":"Cheng","year":"2019","journal-title":"J. Formos. Med. Assoc. = Taiwan yi zhi"},{"key":"10.1016\/j.tranon.2026.102719_bib0041","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1038\/srep05012","article-title":"Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis","volume":"4","author":"Wang","year":"2014","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0042","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.eururo.2014.07.034","article-title":"Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study","volume":"68","author":"Fossati","year":"2015","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0043","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41598-020-57618-2","article-title":"Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy","volume":"10","author":"Cheng","year":"2020","journal-title":"Sci. Rep."},{"issue":"1104","key":"10.1016\/j.tranon.2026.102719_bib0044","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190480","article-title":"Accuracy of multiparametric magnetic resonance imaging for detecting extracapsular extension in prostate cancer: a systematic review and meta-analysis","volume":"92","author":"Zhang","year":"2019","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.tranon.2026.102719_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-6-19","article-title":"A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening","volume":"6","author":"Vickers","year":"2008","journal-title":"BMC. Med."},{"issue":"7","key":"10.1016\/j.tranon.2026.102719_bib0046","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv095","article-title":"Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study","volume":"107","author":"Bryant","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.tranon.2026.102719_bib0047","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/1055-9965.EPI-10-1003","article-title":"A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening","volume":"20","author":"Vickers","year":"2011","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"15","key":"10.1016\/j.tranon.2026.102719_bib0048","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2009.24.1968","article-title":"Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication","volume":"28","author":"Vickers","year":"2010","journal-title":"J. clin. oncol. : off. j. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0049","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.eururo.2015.04.028","article-title":"A four-kallikrein panel predicts high-grade cancer on biopsy: independent validation in a community cohort","volume":"69","author":"Braun","year":"2016","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102719_bib0050","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.clgc.2016.12.022","article-title":"A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Prostate Health Index and 4-Kallikrein Panel Score in Predicting Overall and High-grade Prostate Cancer","volume":"15","author":"Russo","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"issue":"21","key":"10.1016\/j.tranon.2026.102719_bib0051","first-page":"3350","article-title":"Biomarkers for Prostate Cancer: From Diagnosis to Treatment","volume":"13","author":"Chen","year":"2023","journal-title":"Diagn. (Basel Switz.)"},{"issue":"23","key":"10.1016\/j.tranon.2026.102719_bib0052","first-page":"5975","article-title":"DD3: a new prostate-specific gene, highly overexpressed in prostate cancer","volume":"59","author":"Bussemakers","year":"1999","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0053","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.yexmp.2010.10.009","article-title":"The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population","volume":"90","author":"Shen","year":"2011","journal-title":"Exp. Mol. Pathol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0054","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.juro.2011.10.133","article-title":"Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion","volume":"187","author":"Salagierski","year":"2012","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0055","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1078-0432.CCR-06-2679","article-title":"The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance","volume":"13","author":"van Gils","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.tranon.2026.102719_bib0056","doi-asserted-by":"crossref","first-page":"13519","DOI":"10.4238\/2015.October.28.13","article-title":"Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer","volume":"14","author":"Coelho","year":"2015","journal-title":"Genet. Mol. Res."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0057","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.urology.2012.11.069","article-title":"Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?","volume":"81","author":"Tombal","year":"2013","journal-title":"Urology."},{"issue":"9","key":"10.1016\/j.tranon.2026.102719_bib0058","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/iju.13734","article-title":"Urinary biomarkers of prostate cancer","volume":"25","author":"Fujita","year":"2018","journal-title":"Int. J. Urol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0059","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","article-title":"Detection of high-grade prostate cancer using a urinary molecular biomarker\u2013based risk score","volume":"70","author":"Van Neste","year":"2016","journal-title":"Eur. Urol."},{"issue":"16","key":"10.1016\/j.tranon.2026.102719_bib0060","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/pros.23065","article-title":"The role of HOXC6 in prostate cancer development","volume":"75","author":"Hamid","year":"2015","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0061","first-page":"393","article-title":"Multiparametric MRI Versus SelectMDx Accuracy in the Diagnosis of Clinically Significant PCa in Men Enrolled in Active Surveillance","volume":"34","author":"Pepe","year":"2020","journal-title":"Vivo (Athens Greece)"},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0062","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12894-019-0561-6","article-title":"Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports","volume":"19","author":"Minnee","year":"2019","journal-title":"BMC. Urol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0063","first-page":"282","article-title":"Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-na\u00efve men","volume":"80","author":"Hendriks","year":"2021","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102719_bib0064","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41391-020-0237-z","article-title":"Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10\u2009ng\/mL","volume":"23","author":"Tutrone","year":"2020","journal-title":"Prostate Cancer Prostatic. Dis."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0065","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41391-023-00675-1","article-title":"ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis","volume":"26","author":"Tutrone","year":"2023","journal-title":"Prostate Cancer Prostatic. Dis."},{"issue":"2","key":"10.1016\/j.tranon.2026.102719_bib0066","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41391-021-00456-8","article-title":"Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies","volume":"25","author":"Margolis","year":"2022","journal-title":"Prostate Cancer Prostatic. Dis."},{"issue":"4","key":"10.1016\/j.tranon.2026.102719_bib0067","first-page":"11224","article-title":"How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care","volume":"29","author":"Moul","year":"2022","journal-title":"Can. J. Urol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0068","first-page":"129","article-title":"Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study","volume":"7","author":"Wojno","year":"2014","journal-title":"Am. Health Drug Benefits"},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0069","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/00045632211041890","article-title":"Tumour markers in prostate cancer: The post-prostate-specific antigen era","volume":"59","author":"Garrido","year":"2022","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.tranon.2026.102719_bib0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.mou.0000165553.17534.e3","article-title":"Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer","volume":"15","author":"Ward","year":"2005","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.tranon.2026.102719_bib0071","doi-asserted-by":"crossref","unstructured":"Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur. Urol. 2014;65:1046\u201355.3. Saini S. PSA and beyond: alternative prostate cancer biomarkers.Cell Oncol (Dordr) 2016;39:97\u2013106.","DOI":"10.1007\/s13402-016-0268-6"},{"issue":"6","key":"10.1016\/j.tranon.2026.102719_bib0072","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2217\/bmm-2021-0479","article-title":"Development and Validation of A Cell Cycle Progression Signature for Decentralized Testing of Men with Prostate Cancer","volume":"16","author":"Kuhl","year":"2022","journal-title":"Biomark. Med."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0073","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41391-019-0197-3","article-title":"Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting","volume":"23","author":"Howard","year":"2020","journal-title":"Prostate Cancer Prostatic. Dis."},{"key":"10.1016\/j.tranon.2026.102719_bib0074","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2015.05.042","article-title":"Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men","volume":"69","author":"Ross","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2026.102719_bib0075","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.eururo.2014.05.039","article-title":"Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort","volume":"67","author":"Cooperberg","year":"2015","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0076","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3390\/cancers14051118","article-title":"Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer","volume":"14","author":"Lorenzin","year":"2022","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.tranon.2026.102719_bib0077","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jmoldx.2015.12.006","article-title":"Application of a clinical whole transcriptome assay for staging and prognosis of prostate cancer diagnosed in needle core biopsy specimens","volume":"18","author":"Knudsen","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.tranon.2026.102719_bib0078","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/RRU.S99997","article-title":"Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis","volume":"8","author":"Lee","year":"2016","journal-title":"ResReports Urol"},{"key":"10.1016\/j.tranon.2026.102719_bib0079","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2016.01.012","article-title":"Decipher genomic classifier measured on prostate biopsy predicts metastasis risk","volume":"90","author":"Klein","year":"2016","journal-title":"Urology."},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0080","first-page":"1","article-title":"Contemporary Role of the Decipher\u00ae Test in Prostate Cancer Management: Current Practice and Future Perspectives","volume":"18","author":"Dalela","year":"2016","journal-title":"Rev. Urol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0081","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.euo.2018.12.007","article-title":"Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery","volume":"2","author":"Van den Broeck","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.tranon.2026.102719_bib0082","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2164-14-690","article-title":"Analytical validation of the Onco type DX prostate cancer assay\u2013a clinical RT-PCR assay optimized for prostate needle biopsies","volume":"14","author":"Knezevic","year":"2013","journal-title":"BMC Genom."},{"issue":"33","key":"10.1016\/j.tranon.2026.102719_bib0083","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Harris","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102719_bib0084","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2017.10.036","article-title":"Genomic markers in prostate cancer decision making","volume":"73","author":"Cucchiara","year":"2018","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102719_bib0085","first-page":"e873","article-title":"Development and validation of the biopsy-based genomic prostate score (GPS) as a predictor of high grade or extracapsular prostate cancer to improve patient selection for active surveillance","volume":"189","author":"Cooperberg","year":"2013","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102719_bib0086","doi-asserted-by":"crossref","first-page":"218","DOI":"10.7326\/ANNALS-24-00700","article-title":"Impact of Genomic Classifiers on Risk Stratification and Treatment Intensity in Patients With Localized Prostate Cancer : A Systematic Review","volume":"178","author":"Tabriz","year":"2025","journal-title":"Ann. Intern. Med."},{"issue":"19","key":"10.1016\/j.tranon.2026.102719_bib0087","doi-asserted-by":"crossref","first-page":"19690","DOI":"10.1002\/cam4.6615","article-title":"Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial","volume":"12","author":"Carbunaru","year":"2023","journal-title":"Cancer Med."},{"issue":"15","key":"10.1016\/j.tranon.2026.102719_bib0088","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.20.02997","article-title":"Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial","volume":"39","author":"Murphy","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0089","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/UPJ.0000000000000281","article-title":"Decisional Regret and Financial Toxicity among Patients with Benign Renal Masses","volume":"9","author":"Mendhiratta","year":"2022","journal-title":"Urol. Pract."},{"key":"10.1016\/j.tranon.2026.102719_bib0090","doi-asserted-by":"crossref","DOI":"10.1177\/17562872221103988","article-title":"Biomarkers for prostate cancer detection and risk stratification","author":"Farha","year":"2022","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.tranon.2026.102719_bib0091","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.3390\/cancers15174270","article-title":"Aggressive prostate cancer in patients treated with active surveillance","volume":"15","author":"Tohi","year":"2023","journal-title":"Cancers. (Basel)"},{"issue":"6","key":"10.1016\/j.tranon.2026.102719_bib0092","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0093","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.2015.223","article-title":"Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort","volume":"113","author":"Cuzick","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2026.102719_bib0094","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.urolonc.2018.03.011","article-title":"Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance","volume":"36","author":"Lin","year":"2018","journal-title":"Urol, Oncol"},{"issue":"4","key":"10.1016\/j.tranon.2026.102719_bib0095","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clgc.2021.01.003","article-title":"Personalizing localized prostate cancer: validation of a combined clinical cell-cycle risk (CCR) score threshold for prognosticating benefit from multimodality therapy","volume":"19","author":"Tward","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.tranon.2026.102719_bib0096","unstructured":"Tward J, LenzL, IiFlake DDet al. The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. Int, J. Radiat, Oncol, Biol, Phys doi:10.1016\/j.ijrobp.2021.09.034(2021) (Epub ahead of print)."},{"issue":"6","key":"10.1016\/j.tranon.2026.102719_bib0097","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/pme-2019-0084","article-title":"Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score","volume":"16","author":"Kaul","year":"2019","journal-title":"Per. Med."},{"key":"10.1016\/j.tranon.2026.102719_bib0098","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bju.15998","article-title":"Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging","volume":"132","author":"Morote","year":"2023","journal-title":"BJu Int."},{"issue":"12","key":"10.1016\/j.tranon.2026.102719_bib0099","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0100","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s12094-019-02170-3","article-title":"The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: A systematic review and meta-analysis","volume":"22","author":"Liu","year":"2020","journal-title":"Clin. Transl. Oncol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102719_bib0101","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/genes11070719","article-title":"PTEN alterations and their role in cancer management: Are we making headway on precision medicine?","volume":"11","author":"Fusco","year":"2020","journal-title":"Genes. (Basel)"},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0102","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.apjtm.2016.09.011","article-title":"miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study","volume":"10","author":"Yang","year":"2017","journal-title":"Asian Pac. J. Trop. Med."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0103","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6603924","article-title":"FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome","volume":"97","author":"Yoshimoto","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"39","key":"10.1016\/j.tranon.2026.102719_bib0104","doi-asserted-by":"crossref","first-page":"65566","DOI":"10.18632\/oncotarget.19217","article-title":"PTEN loss detection in prostate cancer: Comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort","volume":"8","author":"Lotan","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.tranon.2026.102719_bib0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/modpathol.2015.136","article-title":"Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer","volume":"29","author":"Murphy","year":"2016","journal-title":"Mod. Pathol."},{"issue":"17","key":"10.1016\/j.tranon.2026.102719_bib0106","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.3390\/cancers17172862","article-title":"Prognostic significance of PTEN loss in prostate cancer: A meta-analysis of Gleason grade and clinical outcomes","volume":"17","author":"Kisiel","year":"2025","journal-title":"Cancers. (Basel)"},{"issue":"12","key":"10.1016\/j.tranon.2026.102719_bib0107","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1038\/bjc.2013.248","article-title":"Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer","volume":"108","author":"Cuzick","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0108","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102719_bib0109","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/uro2.32","article-title":"Current and emerging tissue-based molecular biomarkers for prostate cancer management: a narrative review","volume":"1","author":"Singh","year":"2023","journal-title":"UroPrecision"},{"key":"10.1016\/j.tranon.2026.102719_bib0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.676716","article-title":"Tissue-based biomarkers for the risk stratification of men with clinically localized prostate cancer","author":"Basourakos","year":"2021","journal-title":"Oncol Front"},{"key":"10.1016\/j.tranon.2026.102719_bib0111","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.3390\/cancers13174251","article-title":"Biomarker in active surveillance for prostate cancer: a systematic review","volume":"13","author":"Manceau","year":"2021","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.tranon.2026.102719_bib0112","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4111\/icu.20240229","article-title":"Prostate cancer theragnostics biomarkers: an update","volume":"65","author":"Am","year":"2024","journal-title":"Investig. Clin. Urol."},{"issue":"18","key":"10.1016\/j.tranon.2026.102719_bib0113","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/sj.onc.1210070","article-title":"Diversity of TMPRSS2-ERG fusion transcripts in the human prostate","volume":"26","author":"Clark","year":"2007","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.tranon.2026.102719_bib0114","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/PDM.0b013e31829e0484","article-title":"A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort","volume":"22","author":"Svensson","year":"2014","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"9","key":"10.1016\/j.tranon.2026.102719_bib0115","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/modpathol.3800903","article-title":"Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues","volume":"20","author":"Tu","year":"2007","journal-title":"Mod. Pathol."},{"issue":"14","key":"10.1016\/j.tranon.2026.102719_bib0116","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/sj.onc.1210843","article-title":"Complex patterns of ETS gene alteration arise during cancer development in the human prostate","volume":"27","author":"Clark","year":"2008","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.tranon.2026.102719_bib0117","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1158\/1078-0432.CCR-07-5194","article-title":"Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications","volume":"14","author":"Mosquera","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.tranon.2026.102719_bib0118","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1593\/neo.10726","article-title":"Antibody-based detection of ERG rearrangement-positive prostate cancer","volume":"12","author":"Park","year":"2010","journal-title":"Neoplasia"},{"issue":"8","key":"10.1016\/j.tranon.2026.102719_bib0119","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/modpathol.2011.65","article-title":"Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice","volume":"24","author":"Van Leenders","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.tranon.2026.102719_bib0120","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.623809","article-title":"Androgen-driven fusion genes and chimeric transcripts in prostate cancer","author":"Scaravilli","year":"2021","journal-title":"Cell Dev Biol Front"},{"key":"10.1016\/j.tranon.2026.102719_bib0121","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.clgc.2015.12.001","article-title":"Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: literature review","volume":"14","author":"Sanguedolce","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.tranon.2026.102719_bib0122","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12957-024-03314-8","article-title":"Individualized detection of TMPRSS2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature","volume":"22","author":"Li","year":"2024","journal-title":"World J. Surg. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2026.102719_bib0123","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1586\/14737159.2015.1091729","article-title":"Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay","volume":"15","author":"Alix-Panabi\u00e8res","year":"2015","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0124","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.molmed.2020.01.012","article-title":"Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living","volume":"26","author":"Heitzer","year":"2020","journal-title":"Trends. Mol. Med."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.critrevonc.2011.05.004","article-title":"Circulating tumor cells in prostate cancer: a potential surrogate marker of survival","volume":"81","author":"Doyen","year":"2012","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"issue":"6","key":"10.1016\/j.tranon.2026.102719_bib0126","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.eururo.2020.12.037","article-title":"Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer","volume":"79","author":"Casanova-Salas","year":"2021","journal-title":"Eur. Urol."},{"issue":"23","key":"10.1016\/j.tranon.2026.102719_bib0127","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","article-title":"Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer","volume":"13","author":"Danila","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.tranon.2026.102719_bib0128","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3390\/cancers5041676","article-title":"Circulating tumor cells in prostate cancer","volume":"5","author":"Hu","year":"2013","journal-title":"Cancers. (Basel)"},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1373\/clinchem.2018.287102","article-title":"Circulating tumor cells in prostate cancer: from discovery to clinical utility","volume":"65","author":"Pantel","year":"2019","journal-title":"Clin. Chem."},{"issue":"12","key":"10.1016\/j.tranon.2026.102719_bib0130","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ncponc0664","article-title":"Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials","volume":"3","author":"leming","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"9","key":"10.1016\/j.tranon.2026.102719_bib0131","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/biomedicines9091179","article-title":"Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management","volume":"9","author":"Cie\u015blikowski","year":"2021","journal-title":"Biomedicines."},{"issue":"6","key":"10.1016\/j.tranon.2026.102719_bib0132","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/PPO.0b013e31823e69ac","article-title":"Circulating tumors cells as biomarkers: progress toward biomarker qualification","volume":"17","author":"Danila","year":"2011","journal-title":"Cancer J."},{"issue":"15","key":"10.1016\/j.tranon.2026.102719_bib0133","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3390\/cancers17152589","article-title":"Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management","volume":"17","author":"Kopytov","year":"2025","journal-title":"Cancers. (Basel)"},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0134","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3390\/jpm13050705","article-title":"Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction","volume":"13","author":"Ying","year":"2023","journal-title":"J. Pers. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s007740170059","article-title":"Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy","volume":"19","author":"Tamada","year":"2001","journal-title":"J. Bone Miner. Metab."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0136","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ijc.20314","article-title":"Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications","volume":"111","author":"Jung","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0137","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/03936155231154662","article-title":"Prognostic value of alkaline phosphatase and bone-specific alkaline phosphatase in breast cancer: A systematic review and meta-analysis","volume":"38","author":"Jiang","year":"2023","journal-title":"Int. J. Biol. Markers"},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0138","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1146\/annurev-physiol-030212-183656","article-title":"The androgen receptor in health and disease","volume":"75","author":"Matsumoto","year":"2013","journal-title":"Annu. Rev. Physiol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0139","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: Structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"4","key":"10.1016\/j.tranon.2026.102719_bib0140","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.bbrc.2003.11.075","article-title":"The polyglycine and polyglutamine repeats in the androgen receptor gene in Japanese and Caucasian populations","volume":"312","author":"Sasaki","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.tranon.2026.102719_bib0141","doi-asserted-by":"crossref","first-page":"R146","DOI":"10.1530\/EC-17-0118","article-title":"Clinical relevance of androgen receptor alterations in prostate cancer","volume":"6","author":"Jernberg","year":"2017","journal-title":"Endocr. Connect."},{"issue":"7","key":"10.1016\/j.tranon.2026.102719_bib0142","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/iju.12146","article-title":"Transcriptional network of androgen receptor in prostate cancer progression","volume":"20","author":"Takayama","year":"2013","journal-title":"Int. J. Urol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0143","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/138920209787581307","article-title":"The role of androgen receptor mutations in prostate cancer progression","volume":"10","author":"Brooke","year":"2009","journal-title":"Curr. Genom."},{"issue":"21","key":"10.1016\/j.tranon.2026.102719_bib0144","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.3390\/cancers13215417","article-title":"Androgen receptor signaling in prostate cancer and therapeutic strategies","volume":"13","author":"Jacob","year":"2021","journal-title":"Cancers. (Basel)"},{"issue":"12","key":"10.1016\/j.tranon.2026.102719_bib0145","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.3390\/cancers13122939","article-title":"Evaluation of darolutamide (ODM201) efficiency on androgen receptor mutants reported to date in prostate cancer patients","volume":"13","author":"Lallous","year":"2021","journal-title":"Cancers. (Basel)"},{"issue":"13","key":"10.1016\/j.tranon.2026.102719_bib0146","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","article-title":"Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance","volume":"68","author":"Dehm","year":"2008","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.tranon.2026.102719_bib0147","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2013.05.012","article-title":"Words of wisdom: Re: Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines","volume":"64","author":"Luo","year":"2013","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0148","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","article-title":"Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Antonarakis","year":"2015","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.tranon.2026.102719_bib0149","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3310\/nihropenres.13284.2","article-title":"Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial","volume":"2","author":"Gravestock","year":"2023","journal-title":"NIHR. Open. Res."},{"issue":"13","key":"10.1016\/j.tranon.2026.102719_bib0150","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter study of circulating tumor cell AR-V7 and taxane benefit in men with metastatic castration-resistant prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2026.102719_bib0151","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.tranon.2026.102719_bib0152","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2026.102719_bib0153","unstructured":"ClinicalTrials.gov, U.S. National Library of Medicine. Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and in Combination with Enzalutamide in Participants with Metastatic Castrate-Resistant Prostate Cancer."},{"key":"10.1016\/j.tranon.2026.102719_bib0154","article-title":"Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance","volume":"15","author":"Li","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2026.102719_bib0155","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-69080-3_23","article-title":"Androgen Receptor Coactivators and Prostate Cancer","volume":"617","author":"Agoulnik","year":"2008","journal-title":"Horm. Carcinog. V. Adv. Exp. Med. Biol."},{"issue":"18","key":"10.1016\/j.tranon.2026.102719_bib0156","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.3390\/ijms21186622","article-title":"Metabolic Roles of Androgen Receptor and Tip60 in Androgen-Dependent Prostate Cancer","volume":"21","author":"Tan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102719_bib0157","article-title":"Comparison of CTCs and AR-V7 as clinical biomarkers in mCRPC","volume":"12","author":"Schlack","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2026.102719_bib0158","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2147\/CMAR.S506423","article-title":"Real-world treatment patterns and survival outcomes in metastatic hormone-sensitive prostate cancer: Insights from a retrospective cohort study","volume":"17","author":"Tashkandi","year":"2025","journal-title":"Cancer Manage Res."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0159","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3390\/curroncol31030086","article-title":"Review on the role of BRCA mutations in genomic screening and risk stratification of prostate cancer","volume":"31","author":"Kalampokis","year":"2024","journal-title":"Curr. Oncol."},{"issue":"9","key":"10.1016\/j.tranon.2026.102719_bib0160","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/cancers15092435","article-title":"Frequency of germline and somatic BRCA1 and BRCA2 mutations in prostate cancer: An updated systematic review and meta-analysis","volume":"15","author":"Valsecchi","year":"2023","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.tranon.2026.102719_bib0161","unstructured":"National Comprehensive Cancer Network (NCCN). (2025). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (Version 2.2025).https:\/\/www.nccn.org\/guidelines\/guidelines-detail?Category=1&id=1459."},{"issue":"9","key":"10.1016\/j.tranon.2026.102719_bib0162","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.3390\/cancers15092662","article-title":"Roles of the PARP inhibitor in BRCA1- and BRCA2-pathogenic mutated metastatic prostate cancer: Direct functions and modification of the tumor microenvironment","volume":"15","author":"Inoue","year":"2023","journal-title":"Cancers. (Basel)"},{"issue":"22","key":"10.1016\/j.tranon.2026.102719_bib0163","first-page":"5957","article-title":"FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA-mutated metastatic castration-resistant prostate cancer","volume":"26","author":"King","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.tranon.2026.102719_bib0164","first-page":"5362","article-title":"Olaparib efficacy in metastatic castration-resistant prostate cancer with BRCA or ATM alterations identified by circulating tumor DNA analysis","volume":"28","author":"Mateo","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.tranon.2026.102719_bib0165","first-page":"123","article-title":"Olaparib monotherapy or combination with abiraterone in BRCA-mutated metastatic castration-resistant prostate cancer: Insights from the PROfound and PROpel studies","volume":"84","author":"Clarke","year":"2023","journal-title":"Eur. Urol."},{"issue":"28","key":"10.1016\/j.tranon.2026.102719_bib0166","first-page":"3145","article-title":"Niraparib plus abiraterone acetate and prednisone in BRCA-mutated metastatic castration-resistant prostate cancer: Final MAGNITUDE trial results","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0167","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0168","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2741\/e749","article-title":"Hoxb13, a potential prognostic biomarker for prostate cancer","volume":"8","author":"Ouhtit","year":"2016","journal-title":"Front. Biosci. (Elite Ed)"},{"key":"10.1016\/j.tranon.2026.102719_bib0169","first-page":"124","article-title":"HOXB13 promotes androgenindependent growth of LNCaP prostate cancer cells by activation of E2F signaling","volume":"9","author":"Jung","year":"2009","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2026.102719_bib0170","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102719_bib0171","unstructured":"A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Lin X, Qu L, Chen Z, et al. Prostate."},{"key":"10.1016\/j.tranon.2026.102719_bib0172","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1371\/journal.pone.0132728","article-title":"Identification of two novel HOXB13 germline mutations in Portuguese prostate cancer patients","volume":"10","author":"Maia","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.tranon.2026.102719_bib0173","first-page":"14","article-title":"Inherited predisposition to prostate cancer: from gene discovery to clinical impact","volume":"128","author":"Cooney","year":"2017","journal-title":"Am Clin Clim. Assoc"},{"key":"10.1016\/j.tranon.2026.102719_bib0174","unstructured":"National Comprehensive Cancer Network (NCCN). (2023). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 1.2023. Section on germline testing. Full text: PDF."},{"issue":"1","key":"10.1016\/j.tranon.2026.102719_bib0175","first-page":"105","article-title":"Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer","volume":"262","author":"Pei","year":"2023","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102719_bib0176","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1158\/1055-9965.EPI-23-0892","article-title":"Isolating the Drivers of Racial Inequities in Prostate Cancer Treatment","volume":"33","author":"Hammarlund","year":"2024","journal-title":"Cancer Epidemiol Biomark. Prev"},{"key":"10.1016\/j.tranon.2026.102719_bib0177","first-page":"212","article-title":"Racial disparities in prostate cancer mortality: a model-based analysis","volume":"62","author":"Etzioni","year":"2023","journal-title":"JNCI Monogr."},{"key":"10.1016\/j.tranon.2026.102719_bib0178","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s10555-024-10193-8","article-title":"Racial disparity in prostate cancer: an outlook in genetic and molecular landscape","volume":"43","author":"Kaushal","year":"2024","journal-title":"Cancer Metastasis Rev."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0179","first-page":"289","article-title":"Prostate cancer disparities in outcomes and care: a critical review","volume":"19","author":"Mahal","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.tranon.2026.102719_bib0180","first-page":"448","article-title":"Rising metastatic prostate cancer rates but narrowing racial gap","volume":"23","author":"Shoag","year":"2025","journal-title":"BMC. Med."},{"key":"10.1016\/j.tranon.2026.102719_bib0181","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41582-020-0362-2","article-title":"Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities","volume":"16","author":"Davis","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.tranon.2026.102719_bib0182","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/469156a","article-title":"Bring on the biomarkers","volume":"469","author":"Poste","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102719_bib0183","first-page":"256","article-title":"Cancer biomarker discovery and validation","volume":"4","author":"Goossens","year":"2015","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102719_bib0184","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9086829","article-title":"Challenges in cancer biomarker discovery exemplified by the identification of diagnostic MicroRNAs in prostate tissues","volume":"2020","author":"Ambrozkiewicz","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.tranon.2026.102719_bib0185","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.critrevonc.2017.11.007","article-title":"Biomarkers in prostate cancer - Current clinical utility and future perspectives","volume":"120","author":"Kretschmer","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.tranon.2026.102719_bib0186","first-page":"105","article-title":"Tumor heterogeneity: causes and consequences","volume":"1805","author":"Marusyk","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tranon.2026.102719_bib0187","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/EDBK_205441","article-title":"Practical methods for integrating genetic testing into clinical practice for advanced prostate cancer","volume":"38","author":"Cheng","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.tranon.2026.102719_bib0188","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102719_bib0189","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102719_bib0190","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.18632\/oncotarget.28015","article-title":"Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions","volume":"12","author":"Scott","year":"2021","journal-title":"Oncotarget."},{"issue":"10","key":"10.1016\/j.tranon.2026.102719_bib0191","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40273-023-01292-5","article-title":"Health economic evidence and modeling challenges for liquid biopsy assays in cancer management: A systematic literature review","volume":"41","author":"Fagery","year":"2023","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.tranon.2026.102719_bib0192","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.3390\/curroncol29070400","article-title":"Emerging biomarker-guided therapies in prostate cancer","volume":"29","author":"Deluce","year":"2022","journal-title":"Curr. Oncol."},{"issue":"45","key":"10.1016\/j.tranon.2026.102719_bib0193","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1038\/s41388-020-01479-6","article-title":"Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors","volume":"39","author":"Zhu","year":"2020","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.tranon.2026.102719_bib0194","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/iju.15424","article-title":"Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries","volume":"31","author":"Obinata","year":"2024","journal-title":"Int. J. Urol."},{"issue":"20","key":"10.1016\/j.tranon.2026.102719_bib0195","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A phase Ib\/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.tranon.2026.102719_bib0196","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/humu.22046","article-title":"The androgen receptor gene mutations database: 2012 update","volume":"33","author":"Gottlieb","year":"2012","journal-title":"Hum. Mutat."},{"issue":"6","key":"10.1016\/j.tranon.2026.102719_bib0197","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.tranon.2026.102719_bib0198","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.eururo.2017.08.027","article-title":"Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression","volume":"73","author":"Ren","year":"2018","journal-title":"Eur, Urol"},{"key":"10.1016\/j.tranon.2026.102719_bib0199","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/metabo9050082","article-title":"Multi-Omics Analyses Detail Metabolic ReprogramminginLipids, Carnitines, and Use of Glycolytic Intermediates between Prostate Small Cell Neuroendocrine Carcinoma and Prostate Adenocarcinoma","volume":"9","author":"Gao","year":"2019","journal-title":"Metabolites."},{"key":"10.1016\/j.tranon.2026.102719_bib0200","article-title":"Deep Learning-Based Multi-Omics Integration Robustly Predicts Relapse in Prostate Cancer","volume":"12","author":"Wei","year":"2022","journal-title":"Front, Oncol"},{"key":"10.1016\/j.tranon.2026.102719_bib0201","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12967-019-02185-y","article-title":"Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer","volume":"18","author":"Kiebish","year":"2020","journal-title":"J. Transl, Med"},{"key":"10.1016\/j.tranon.2026.102719_bib0202","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nature07762","article-title":"Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression","volume":"457","author":"Sreekumar","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102719_bib0203","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/biom9100591","article-title":"Investigating the Multi-Target Pharmacological Mechanism of Hedyotis diffusa Willd Acting on Prostate Cancer: A Network Pharmacology Approach","volume":"9","author":"Song","year":"2019","journal-title":"Biomolecules."},{"key":"10.1016\/j.tranon.2026.102719_bib0204","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4103\/aja20243","article-title":"Single-cell analysis revealing the metabolic landscape of prostate cancer","volume":"26","author":"Wang","year":"2024","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.tranon.2026.102719_bib0205","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s11658-023-00450-z","article-title":"Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment","volume":"28","author":"Yu","year":"2023","journal-title":"Cell Mol, Biol, Lett"},{"key":"10.1016\/j.tranon.2026.102719_bib0206","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41525-024-00401-3","article-title":"Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer","volume":"9","author":"Saha","year":"2024","journal-title":"NPJ Genom, Med"},{"key":"10.1016\/j.tranon.2026.102719_bib0207","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-023-01393-9","article-title":"Integrative multi-omics and drug-response characterization of patient-derived prostate cancer primary cells","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct, Target, Ther"},{"key":"10.1016\/j.tranon.2026.102719_bib0208","article-title":"Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer","volume":"3","author":"De Vargas Roditi","year":"2022","journal-title":"Cell Rep, Med"},{"key":"10.1016\/j.tranon.2026.102719_bib0209","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202305724","article-title":"Integration Analysis of Single-Cell Multi-Omics Reveals Prostate Cancer Heterogeneity","volume":"11","author":"Bian","year":"2024","journal-title":"Adv, Sci"},{"key":"10.1016\/j.tranon.2026.102719_bib0210","first-page":"97","article-title":"Saliva-based polygenic risk scores and AI-enhanced imaging for prostate cancer screening beyond PSA","volume":"8","author":"Li","year":"2025","journal-title":"Ann Urol Oncol"},{"key":"10.1016\/j.tranon.2026.102719_bib0211","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4111\/icu.20240456","article-title":"Evaluating prostate cancer diagnostic methods: the role and relevance of digital rectal examination in modern era","volume":"66","author":"Chung","year":"2025","journal-title":"Investig. Clin. Urol."},{"key":"10.1016\/j.tranon.2026.102719_bib0212","unstructured":"Prostate cancer screening with artificial intelligence-enhanced micro-ultrasound: a comparative study with traditional methods [Preprint] Imran M, Brisbane WG, Su LM, Joseph JP, Shao W. arXiv. 2025;2505:21355. [Google Scholar]."},{"key":"10.1016\/j.tranon.2026.102719_bib0213","unstructured":"Multimodal MRI-ultrasound AI for prostate cancer detection outperforms radiologist MRI interpretation: a multi-center study [Preprint] Jahanandish H, Sang S, Li CX, et al. arXiv. 2025;2502:146. [Google Scholar]."},{"key":"10.1016\/j.tranon.2026.102719_bib0214","doi-asserted-by":"crossref","first-page":"0","DOI":"10.12659\/MSM.949300","article-title":"A review of circulating tumor DNA (ctDNA) and the liquid biopsy in cancer diagnosis, screening, and monitoring treatment response","volume":"31","author":"Parums","year":"2025","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.tranon.2026.102719_bib0215","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1164\/rccm.202109-2019OC","article-title":"Multidimensional cell-free DNA fragmentomic assay for detection of early-stage lung cancer","volume":"207","author":"Wang","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.tranon.2026.102719_bib0216","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102719_bib0217","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1158\/1538-7445.AM2024-LB241","article-title":"FateAI: analysis of circulating DNA fragmentomics with an artificial intelligence model for cancer screening","volume":"84","author":"De Falco","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102719_bib0218","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1158\/1538-7445.AM2025-4564","article-title":"Enhancing circulating tumor DNA recovery and liquid biopsy sensitivity with precision liposomal priming agents","volume":"85","author":"Chakraborty","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102719_bib0219","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.3390\/cancers17142334","article-title":"The role of genomic scores in the management of prostate cancer patients: a comprehensive narrative review","volume":"17","author":"Viti","year":"2025","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.tranon.2026.102719_bib0220","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1538-7445.AM2024-2442","article-title":"Blood-based novel mRNA genomic test for screening, early detection, prognosis and monitoring of prostate cancer using a multi-center study","volume":"84","author":"Hashimoto","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102719_bib0221","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1200\/JCO.2025.43.16_suppl.3053","article-title":"Real-time clinical validation of a blood cell-free, mRNA-based GeneVerify test for screening and early diagnosis of prostate cancer","volume":"43","author":"Rawal","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102719_bib0222","first-page":"46","article-title":"A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer","volume":"48","author":"Oka","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2026.102719_bib0223","first-page":"331","article-title":"Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors","volume":"40","author":"Shoup","year":"1999","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2026.102719_bib0224","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s11307-009-0220-5","article-title":"Initial experience with the radiotracer anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC) with PET in renal carcinoma","volume":"11","author":"Schuster","year":"2009","journal-title":"Mol. ImAging Biol."},{"key":"10.1016\/j.tranon.2026.102719_bib0225","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00259-013-2374-2","article-title":"PSMA as a target for radiolabelled small molecules","volume":"40","author":"Eder","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. ImAging"},{"key":"10.1016\/j.tranon.2026.102719_bib0226","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s00259-013-2467-y","article-title":"Comparison of integrated whole-body [11C]choline PET\/MR with PET\/CT in patients with prostate cancer","volume":"40","author":"Souvatzoglou","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. ImAging"},{"issue":"Suppl 1","key":"10.1016\/j.tranon.2026.102719_bib0227","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1007\/s00259-013-2445-4","article-title":"PET\/MR in prostate cancer: technical aspects and potential diagnostic value","volume":"40","author":"Souvatzoglou","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. ImAging"},{"key":"10.1016\/j.tranon.2026.102719_bib0228","first-page":"331","article-title":"Conventional imaging and multiparametric magnetic resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer","volume":"56","author":"Panebianco","year":"2012","journal-title":"Q. J. Nucl. Med. Mol. ImAging"},{"key":"10.1016\/j.tranon.2026.102719_bib0229","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40336-013-0006-2","article-title":"Potential role of PET\/MRI in radiotherapy treatment planning","volume":"1","author":"Thorwarth","year":"2013","journal-title":"Clin. Transl. ImAging"},{"key":"10.1016\/j.tranon.2026.102719_bib0230","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00259-011-1837-6","article-title":"(1)(8)F-Fluorocholine integrated PET\/MRI for the initial staging of prostate cancer","volume":"38","author":"Lord","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. ImAging"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:49:59Z","timestamp":1781509799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":230,"alternative-id":["S1936523326000562"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102719","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102719"}}